Found "Health Policies": 1,084 results
Quality standards for health promotion and disease prevention services in Thailand
1. BackgroundSince 2011 the Ministry of Public Health (MOPH) and the National Health Security Office (NHSO) has collaborated in health promotion and disease prevention program, which aims to provide a high quality of health promotion and disease prevention services for all Thai people. Although the NHSO has indicators for health promotion and disea
Cost-utility analysis of treatment for prevention of osteoporotic fractures
Background: Osteoporosis, a reduction in bone strength, is one of the most significant factors contributing to fractures, particularly in postmenopausal women. It affects not only patients’ life expectancy and quality of life, but also household expenditure on healthcare costs. Various screening methods to identify the risk of developing osteopo
A study of feasibility of investing and access to spirometry service in community hospitals
Spirometry is a pulmonary function test that measures the volume of air exhaled quickly and strongly to assess how well the lung works. Spirometry is a gold standard of diagnosis, which distinguishes between chronic obstructive pulmonary disease (COPD) and asthma. Spirometry, moreover, is used to monitor disease progression, follow up treatment re
Groundwork: Pre-Conditions for Successful Healthcare Priority Setting
The Groundworks Project is a dialogue set up between industry representatives and health systems representatives of LMICs spanning a timeframe of 12 months and including three workshops. The first workshop focuses on agenda setting between a core group of representatives. The second workshop takes on a national perspective and discusses the context
Cost-Effectiveness Analysis of COVID-19 Vaccine Booster Dose in the Thai Setting during the Period of Omicron Variant Predominance
The Thai government implemented COVID-19 booster vaccines to prevent morbidity and mortality during the spreading of the Omicron variant. However, little is known about which types of vaccine should be invested in as the booster dose for the Thai population. This study aims to investigate the most c
How Many People Experience Unsafe Medical Care in Thailand, and How Much Does It Cost under Universal Coverage Scheme?
Adverse events and medical harm comprise major health concerns for people all over the world, including Thailand. The prevalence and burden of medical harm must always be monitored, and a voluntary database should not be used to represent national value. The purpose of this study is to estimate the
Research Proposal: Convergence of Digital Health Platforms and Health Information Systems (HIS) Implementation in Thailand (ConvergeDH)
Digital health and Health Information Systems (HIS) are dramatically altering the landscape for health. Thailand achieved Universal Health Coverage (UHC) in 2002. However, the delivery of health services relies heavily on manpower without digitisation, and the COVID-19 pandemic has exposed the lack
Situational Analysis of infectious disease modelling (ID) in Thailand
ID modelling is a mathematical description of the spread of infection (1). Infectious disease (ID) in this study refers to common infectious diseases (whether in humans or animals), including COVID-19. ID models help provide the understanding of the disease natural history, as well as the impact of interventions (e.g., vaccination, social distancin
Preliminary recommendations on the establishment of a regional centre for infectious disease control in ASEAN
“United we stand, divided we fall” is a Thai idiom used to exemplify the importance of staying united and of teamwork and common interests. This idiom is reaffirmed in the context of the COVID-19 pandemic, shown in the global nature of catastrophe and the shared prospects of recovery. However, p
Assessing alternative measures for controlling drug prices (in Thai language)
The study suggests that the price of patented medicine in Thailand should be controlled based on equity pricing and outcome pricing. Equity pricing can be estimated from the international reference price and outcome pricing can be evaluated from therapeutic referencing or the pharmacoeconomic price. Moreover, in a case study of 7 medicines granted
10 / Page